Phenotypic and genotypic comparison of antimicrobial-resistant variants of Escherichia coli and Salmonella Typhimurium isolated from evolution assays with antibiotics or commercial products based on essential oils
Resumen: On account of the widespread development and propagation of antimicrobial-resistant (AMR) bacteria, essential oils (EOs) have emerged as potential alternatives to antibiotics. However, as already observed for antibiotics, recent studies have raised concerns regarding the potential emergence of resistant variants (RVs) to EOs. In this study, we assessed the emergence of RVs in Escherichia coli and Salmonella enterica Typhimurium after evolution assays under extended exposure to subinhibitory doses of two commercial EOs (AEN and COLIFIT) as well as to two antibiotics (amoxicillin and colistin). Phenotypic characterization of RVs from evolution assays with commercial EOs yielded no relevant increases in the minimum inhibitory concentration (MIC) of E. coli and did not even modify MIC values in S. Typhimurium. Conversely, RVs of E. coli and S. Typhimurium isolated from evolution assays with antibiotics showed increased resistance. Genotypic analysis demonstrated that resistance to commercial EOs was associated with enhanced protection against oxidative stress and redirection of cell energy toward efflux activity, while resistance to antibiotics was primarily linked to modifications in the cell binding sites of antibiotics. These findings suggest that AEN and COLIFIT could serve as safe alternatives to antibiotics in combating the emergence and dissemination of antimicrobial resistance within the agrifood system.
Idioma: Inglés
DOI: 10.3390/ph16101443
Año: 2023
Publicado en: Pharmaceuticals 16, 10 (2023), 1443 [18 pp.]
ISSN: 1424-8247

Factor impacto JCR: 4.3 (2023)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 69 / 354 = 0.195 (2023) - Q1 - T1
Categ. JCR: CHEMISTRY, MEDICINAL rank: 20 / 72 = 0.278 (2023) - Q2 - T1

Factor impacto CITESCORE: 6.1 - Pharmaceutical Science (Q2) - Drug Discovery (Q2) - Molecular Medicine (Q2)

Factor impacto SCIMAGO: 0.845 - Pharmaceutical Science (Q1) - Drug Discovery (Q2) - Molecular Medicine (Q2)

Financiación: info:eu-repo/grantAgreement/ES/MICINN/PID2021-123404NB-I00
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Nutrición Bromatología (Dpto. Produc.Animal Cienc.Ali.)
Área (Departamento): Área Tecnología de Alimentos (Dpto. Produc.Animal Cienc.Ali.)


Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.


Exportado de SIDERAL (2024-11-22-12:04:28)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos



 Registro creado el 2023-12-15, última modificación el 2024-11-25


Versión publicada:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)